This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of the Effects of Minocycline on Cognitive Function After Carotid Endarterectomy

This study has been terminated.
(PI moved to a new facility)
Information provided by:
Brigham and Women's Hospital Identifier:
First received: November 17, 2006
Last updated: June 22, 2011
Last verified: June 2011

The primary aim of this protocol is to investigate a possible new, neuroprotective treatment to prevent cognitive deficits that occur after carotid endarterectomy. We will investigate whether a widely used antibiotic agent - minocycline - that has shown neuroprotective effects in animal models of neurological diseases - can reduce the cognitive deficits associated with the surgical procedure of carotid endarterectomy (CEA). Because these cognitive deficits are believed to be a result of small strokes (due to emboli and/or hypoperfusion), this study will provide preliminary data on the use of this drug as a neuroprotective agent in stroke - a leading cause of disability.

(1) The first aim of this study is to examine whether 5 doses of minocycline administered 36 hrs before and 1 dose 12 hrs after the surgical procedure in patients undergoing CEA are effective to reduce the cognitive deficits associated with this procedure as compared with placebo.

a. The null hypothesis is that there is no difference in cognitive performance changes after CEA between the patients that receive placebo or minocycline.

Condition Intervention Phase
Carotid Stenosis Drug: Minocycline Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: A Randomized, Placebo-Controlled Study of the Effects of Minocycline on Cognitive Function After Carotid Endarterectomy

Resource links provided by NLM:

Further study details as provided by Brigham and Women's Hospital:

Primary Outcome Measures:
  • Neuropsychological assessment [ Time Frame: 1 day ]

Enrollment: 4
Study Start Date: October 2006
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Minocycline
    100 mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery
    Other Name: Minocycline 100mg/Placebo 0mg
  Show Detailed Description


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with carotid stenosis 60% or more with a clinical indication of CEA.
  2. Patients that can perform the tests in English.
  3. Women of childbearing age must be non-lactating and surgically sterile or using an effective method of birth control and have a negative pregnancy test (adequate birth control includes use of intra uterine device, or a barrier method, e.g. condom, diaphragm).
  4. Ages Eligible for Study: 18 Years - 90 Years
  5. Genders Eligible for Study: Both

Exclusion Criteria:

  1. Known hypersensitivity to tetracyclines
  2. Advanced cardiac, pulmonary or renal disease as assessed by the PCP of the patient.
  3. Previous strokes with important clinical neurological deficits.
  4. Pregnancy, breast-feeding or lactating
  5. Baseline MMSE score less or equal to 20.
  6. Female subjects on oral contraceptives.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00401921

United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Brigham and Women's Hospital
Principal Investigator: Robert Friedlander, MD Brigham and Women's Hospital
  More Information

Responsible Party: Robert Friedlander, MD, Brigham & Women's Hospital Identifier: NCT00401921     History of Changes
Other Study ID Numbers: 2006-P-001225
Study First Received: November 17, 2006
Last Updated: June 22, 2011

Additional relevant MeSH terms:
Carotid Stenosis
Carotid Artery Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Anti-Bacterial Agents
Anti-Infective Agents processed this record on June 22, 2017